Canadian Study NeoPancONE Focuses on Biomarker Validation

You don’t need to be a scientist to understand the concept of biomarkers.

They are simply characteristics of the body that can be measured. Your temperature, blood pressure, glucose, and cholesterol readings are all good examples of biomarkers that can inform your doctor about your health. Clinicians and researchers rely on biomarkers for many applications including diagnosis, disease staging, monitoring a clinical response to a drug, and disease prognosis, among others.

Jennifer Knox, M.D., FRCPC, codirector of the Wallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, Toronto

NeoPancONE Idea Springs From COMPASS Trial Discoveries

At the 2019 Gastrointestinal Cancer Symposium researchers presented data from the Canadian COMPASS trial. The trial prospectively recruited patients prior to first-line chemotherapy for tumor whole-genome and RNA sequencing.

More About NeoPancONE

The main objective of the study is to assess disease-free survival in resectable pancreatic cancer patients treated with perioperative mFOLFIRINOX according to their baseline GATA6 expression level. Among other objectives, the study also hopes to establish the general feasibility of perioperative chemotherapy more broadly in the Canadian medical environment for resectable pancreatic cancer patients.

For More Information

To learn more about the NeoPancONE trial, contact Anna Dodd, Hepatobiliary Oncology Research Program Manager, Wallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre.

A platform that enables doctors, scientists, and patients to share fast-breaking info on potentially life-saving pancreatic cancer treatments & clinical trials.